1 withdrawn. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Progression: new trials by email Literature Review of Progression trials Research Report on Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma Famitinib, Ifosfamide, Camrelizumab - Effect of Drugs, Progression | Phase 1 / Phase 2 | Withdrawn | Peking University People's Hospital | 2019-08-15 | 2020-05-19 |
Disease Progression (1) · Neoplasms (1)
Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Ifosfamide (1) · camrelizumab (1) · famitinib (1)
Peking University People's Hospital (1)
China (1)